Manuel Tissm
Member
Hi amandine,the frequencys between 6000khz and 8000khz i showed an improvement of roughly 20db
When do you know if you took placebo or the real drug?
Hi amandine,the frequencys between 6000khz and 8000khz i showed an improvement of roughly 20db
I dont understand if the drug is so safe, why trial is only 1 month!!?? probably will need 3 months or more to see some noticiable effect as happens with troabalt, i think it will depend a lot of the onset timeA mild improvement,but of course this could be down to anything!
Unfortunately they will never let me know!
I dont understand if the drug is so safe, why trial is only 1 month!!?? probably will need 3 months or more to see some noticiable effect as happens with troabalt, i think it will depend a lot of the onset time
I dont understand if the drug is so safe, why trial is only 1 month!!?? probably will need 3 months or more to see some noticiable effect as happens with troabalt, i think it will depend a lot of the onset time
I dont understand if the drug is so safe, why trial is only 1 month!!?? probably will need 3 months or more to see some noticiable effect as happens with troabalt, i think it will depend a lot of the onset time
This actually scares me a lot.
They should really test people for different time frames to see what gives the best results.
It would be devastating if they just say it doesn't work while it only needed more time to kick in.
4 weeks is possibly nowhere near enough time!
Let's hope for the best!
They might need to up the dosage too.
I'm not a researcher or a scientist but this is bit silly to have a set dose and a set time frame.
More variability would certainly give better picture as to what may be more beneficial.
Then more trials and by the time the drug comes to market, it will 2999! Lets wait for cure till then, suffering this dreaded curse!!I received an email from one of the researchers this week to say that the results probably wont be available till the end of this year.....just so you know......until then...lets just sit tight and wait......
My mother has an appointment in Tampa, FL in the next 2 weeks to enter the autifony study for age related hearing loss. This is probably a screening, but she seems to fit all there criteria so I hope she is entered into the program.
maybe it is a good idea if you google the name of this thread AUTIFONY ... or read the start of it.Who are the Doctors/Researchers running this Trial Study ? What exactly are they doing...try drugs or a device on subjects? Would you be able to provide that info. to curious ones here? Thx
I think we should let the people conducting the research conduct their research. Ultimately they are conducting it in a way that they feel is the most beneficial for learning about the results of the study and are not conducting it to give its users a cure or relief from tinnitus, although if users experience any, that has to be a bonus.
If I recall correctly, the phase-I trial enlisted healthy volunteers for a 3-week course of the drug (possibly at a lower dose, 600mg, if I recall correctly). The treatment course for the phase-II trial is 4 weeks (for sure). I have been in contact with a researcher involved with trial several times. While the person did not explicitly mention the following when I spoke with him/her, the researcher did leave me with the impression that they are merely trying to establish whether the active compound of AUT-63 has some kind of efficacy (in humans). For instance, the person was unwilling to even attempt to answer as to whether AUT-63 would be curative or require life-long treatment to maintain suppression of symptoms of tinnitus. The person said - if I recall correctly: "It's early days still..."So what exactly is the purpose of this research/trial if not to find a cure???
The above is actually quite relevant/unique insight into the drug (as well as Autifony's own expectations).Q. How soon does the drug start to work?
A. We cannot really be sure. In the acute models tested pre-clinically the beneficial effect was seen quite rapidly, and we know that the effect on the nerve cells themselves is very quick. However, because of the so-called plasticity of the brain, and because the tinnitus will have been present for many months, the effects may not start to be felt until after days or even a week or more on the drug; perhaps even longer. It is for this reason that if somebody joins the study it is really important for them to stay right to the end.
If I recall correctly, the phase-I trial enlisted healthy volunteers for a 3-week course of the drug (possibly at a lower dose, 600mg, if I recall correctly). The treatment course for the phase-II trial is 4 weeks (for sure). I have been in contact with a researcher involved with trial several times. While the person did not explicitly mention the following when I spoke with him/her, the researcher did leave me with the impression that they are merely trying to establish whether the active compound of AUT-63 has some kind of efficacy (in humans). For instance, the person was unwilling to even attempt to answer as to whether AUT-63 would be curative or require life-long treatment to maintain suppression of symptoms of tinnitus. The person said - if I recall correctly: "It's early days still..."
Autifony Therapeutics did offer a little bit of insight themselves as to how soon the effects of the drug could be expected to be observed in humans:
The above is actually quite relevant/unique insight into the drug (as well as Autifony's own expectations).
My take on the whole matter (based on my collective information from the researcher) and knowledge in general is that the "real work" starts in phase-III. If phase-II is successful, that is...
attheedgeofscience
09/APR/2015.
by the way what do you think of the low laser therapy ... by Dr Wilden ... They have removed our postsAll this talk about fake people is odd...They will all have tinnitus.
Well, hopefully phase 3 isn't so strict....Also, maybe they'd have a follow-up treatment like AM-101.
Well - I did, as the Trial's peculiar name was "Autifony" (True term "Autophony", ironically is a classification under their long exclusions criteria list). Anyway, the clinical trial is based only in UK and as usual, the Trial evaluates a very specific, small criteria of subjects ingesting 800 mg of drug AUT00063 vs. placebo for 28 days of short-term testing: 150 subjects among twelve hospitals in UK = only 12 to 13 subjects!maybe it is a good idea if you google the name of this thread AUTIFONY ... or read the start of it.
Because they do not want a highly heterogeneous mass of test subjects with various sub-types of tinnitus. That's why...The question is WHY they will NOT test any other subjects under their long "Exclusions" criteria list, which most T sufferers have. Why not?
Yes. And...?Obviously, the "researchers" already know the short-term results from animal lab studies.
To my knowledge Autifony Therapeutics is a privately funded company with 3 main non-government investors. To the extent that funding has indeed been obtained from the UK government, perhaps that is simply because there is an unmet need for a tinnitus treatment and the science is promising (i.e. a first-in-class potassium channel modulator).Million dollar gov. grants require the use of human subjects to pull in investors to get this out on the market asap, for all those baby-boomers/seniors in UK & N. America.
This is a phase-II trial. There is no need to do more thorough testing at this point. Simple as that.WOW- very short criteria and short-term testing (28 days).
Perhaps that group will be studied in a - yes, you guessed it - phase-III trial. Or perhaps the medication will end up not being prescribed for patients with maladies as per the exclusion list.No disclosure of what occurs when patients under their long-exclusion criteria use it?
I didn't know that doctors could prescribe a drug that hasn't entered the market yet. And that was not a question, but a leading question (and without a question mark). All studies go on to a phase-III and a phase-IV post-market release evaluation. There is a reason why the average bench-to-bedside time period is about 10-years for drug candidates: it's because the stuff needs to evaluated properly and to make sure it is safe...Obviously later, GP/ENT Drs will prescribe it regardless, to ALL desperate T sufferers.
I think they won`t test people with depression because they can not give an objective opinion about the results of the drug ... their emotions will play too much in there observations ... offcourse we all know anyone with decent T has some kind of down mood or depression about it ... but it takes an emotional stable person not to call his state a depression but take it as it comes ... with clarity. And so they will be a better judge to the effects of a drug and to give their opinion about it for scientific purposes ...I would say 3/4 of the population (& Veterans) have been diagnosed with "Depression" &/or "Anxiety", especially those who have T. Correct? And, "Otological conditions (including but not limited to....."
Because they do not want a highly heterogeneous mass of test subjects with various sub-types of tinnitus. That's why...
In addition, I might suggest that you unplug your Internet connection permanently, because... "they" could be watching you...
They are looking to prove efficacy in a certain type of patients with tinnitus. If they "cast the net too wide", they will get too many sub-types of tinnitus enrolled in the study. By having too many sub-types, that could lead to efficacy going unproven. Which would mean that the trial would fail already at the phase-II stage (despite being effective in a certain segment of patients). And that would be very unfortunate for the tinnitus community.The only subjects accepted are ones who only had consistent"buzzing" of up to 6 mos. with NO other sinister issues or health issues. Realistic?
Yes. I have earlier on described them here:Do you know who they are?
Autifony is a spin-out from GlaxoSmithKline. You cannot invest in it directly, but you can invest indirectly via (some of) its publicly listed investors which are Imperial Innovations, SV Life Sciences, and Pfizer Venture Investments. However, I don't believe you can necessarily invest in all of these either eg. Pfizer Venture Investments can only be invested in via Pfizer Inc (if I am not mistaken, at least; I hold shares in Pfizer myself, but I haven't had time to check the stock listings today for which companies are available for investments). So investing in Autifony can be a very indirect affair. I believe you can invest directly in Imperial Innovations, however.
If you read what I wrote earlier on in this thread you would have seen that the trial will progress on to a phase-III trial (with more test subjects). This is standard for any trial (not just this one).Anything else? Are you saying one cannot question the validity of this trial, who will not disclose long-term outcomes or even say why they WON'T try it with a larger group of subjects from the general population, rather than just 13 specific subjects at 12 hospitals in 28 days.
Get help. And I am not even being sarcastic.Seems you're pretty defensive on this ClinicalTrial - Reason?
Why don't you take it from an unbiased source, then:You INVEST in SHARES in Corporate Conglomerate Pharmaceutical companies, including Pfizer. Therefore, your information is biased.
@attheedgeofscience thank you for the info as always your such an asset to this forumIf I recall correctly, the phase-I trial enlisted healthy volunteers for a 3-week course of the drug (possibly at a lower dose, 600mg, if I recall correctly). The treatment course for the phase-II trial is 4 weeks (for sure). I have been in contact with a researcher involved with trial several times. While the person did not explicitly mention the following when I spoke with him/her, the researcher did leave me with the impression that they are merely trying to establish whether the active compound of AUT-63 has some kind of efficacy (in humans). For instance, the person was unwilling to even attempt to answer as to whether AUT-63 would be curative or require life-long treatment to maintain suppression of symptoms of tinnitus. The person said - if I recall correctly: "It's early days still..."
Autifony Therapeutics did offer a little bit of insight themselves as to how soon the effects of the drug could be expected to be observed in humans:
The above is actually quite relevant/unique insight into the drug (as well as Autifony's own expectations).
My take on the whole matter (based on my collective information from the researcher) and knowledge in general is that the "real work" starts in phase-III. If phase-II is successful, that is...
attheedgeofscience
09/APR/2015.
Obtained: 24/DEC/2014.Dear Jakob,
You can read more about the trail as it progresses via the Autifony website:
http://www.autifonytherapeutics.com/autifony-tinnitus-phase-IIa-trial.asp
Participants are being screened and enrolled at present, but the study has only just opened at the sites. All participants are ´blinded´ which means that neither they nor the clinical staff know whether they receive the real active drug or a placebo dummy drug. It is not therefore appropriate top ask about interim results in an ongoing randomised clinical trial.
We are actively reviewing the entry criteria as the study progresses. The current details of the study have been registered at this clinical site:
https://clinicaltrials.gov/ct2/show/NCT02315508?term=tinnitus&rank=85
Hope this is informative.
Obtained: 21/AUG/2014.Dear Jakob,
The trial that you have heard about is an early phase clinical study which means that even if the results are positive, the drug still needs to undergo much more testing and evaluation before it can reach the market. The study has not yet been approved by the regulatory authorities, this is in progress at the moment so it won't be open until later this year. This explains why the company have been quite cautious in what they are able to say.
When the study does open, it is likely that some study sites will accept non-UK nationals who speak good English. However, there are strict criteria for eligibility and we will not be able to recruit all tinnitus sufferers onto the study.
Thanks for your interest.